Abstract

To investigate the effect of montelukast on elderly patients with bronchial asthma and the effects of serum transforming growth factor β1 and cysteinyl leukotriene, 150 patients with bronchial asthma enrolled in the Central Hospital of Shanghai Jingan District between October 2016 to October 2018, and those who met the clinical diagnostic criteria were included. All patients were given antispasmodic and antiinfective treatment after admission. The study group (75 cases) were administered orally montelukast chewable tablets, while the control group (75 cases) was not given montelukast. Comparison of the efficacy of the two groups and lung function indicators before and after treatment, such as 1 second forced expiratory volume, first second forced expiratory volume versus forced vital capacity ratio (1 second forced expiratory volume/versus forced vital capacity), first second forced expiratory volume as predicted percentage and changes in the levels of serum transforming growth factor-β1 and cysteinyl leukotriene. The effective rate of treatment in the study group was higher than that in the control group (93.33 % vs 78.67 %, p<0.05). The first second forced expiratory volume, 1 second forced expiratory volume/versus forced vital capacity and percentage of first second forced expiratory volume/predicted of the study group were significantly increased after treatment (p<0.05), and higher than those of the control group (p<0.05). The levels of transforming growth factor-β1 and cysteinyl leukotriene in the study group were significantly decreased before treatment (p<0.05), and were lower than those in the control group (p<0.05). Montelukast treatment of bronchial asthma in the elderly can significantly improve lung function and improve clinical outcomes. Its mechanism of action may be related to the reduction of transforming growth factor β1 and cysteinyl leukotriene levels.